Mild Cognitive Impairment (MCI) with Neuroimaging-biomarkers allows for an early diagnosis of Alzheimer'sdisease in the preclinicalstages. In patients with late-onset Alzheimer's disease, researchers usedstructural and functional magnetic resonance imaging (MRI), advanced MRItechniques (diffusion tensor imaging, magnetic resonancespectroscopy, and perfusion), positron emission tomography with CSF protein levels, fluorodeoxyglucose, amyloidtracers, and other neurochemical tracers. These imaging biomarkers' complextests are used to predict disease development early on and improve theassessment of therapeutic efficacy in these diseases in future clinical trials.
Related:
Dementia Forum | DementiaCongress | DementiaCouncil | DementiaEvents | Neurologycongress | DementiaConference | NeurologyConference | Dementiameetings | DementiaSummit | Neuroscienceconference.
RelatedAssociations:
Dementia Societyof America | Lewy BodyDementia Association | Fisher centerfor Alzheimer’s Research Foundation | Dementia Association| AlzheimerSociety of Canada | Alzheimer’sSociety of Ireland | Alzheimer’sDisease International (ADI) | Alzheimer’s ResearchUK | AcousticNeuroma Association | Alzheimer’sEurope Association | AicardiSyndrome Foundation and Alliance for Aging Research | ALS Therapydevelopment Institute | Alzheimer’sand Related disorders Society of India | Alzheimer’sResearch & Prevention Foundation | ALSassociation and ALS Therapy Development Institute | Alternating Hemiplegiaof Childhood foundation and Alzheimer’s Drug Discovery Foundation.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
